{"id":"79c2677e-6994-5337-8f4b-ebec2f9f51b6","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-the-free-acid-is-required","predicate":"limits","statement":"Conversion of the carboxylate moiety of flurbiprofen to an ester or amide abolishes slow tight-binding behaviour regardless of halogenation state, and contrary to prior predictions a halogen substituent is not sufficient to confer slow tight-binding behaviour.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"a6674d38-87de-5e7c-aae1-d932373951c6","mechanism_event_label":"Cap the acid group and the drug can no longer settle into the slow, tenacious kind of binding.","subject":{"id":"3252e719-ac25-56c8-b944-dd1f3a7cd1dc","slug":"carboxylate-anchor","display_name":"The free carboxylate group of a 2-arylpropionic acid inhibitor","entity_type_key":"protein_state"},"object":{"id":"8a4b95c3-cebe-580a-b5a4-3b1aad8b8a1d","slug":"time-dependent-inhibition","display_name":"Time-dependent, slowly reversible inhibition of cyclooxygenase","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"a6674d38-87de-5e7c-aae1-d932373951c6","stable_key":"3238e4f0-8d45-5c72-8624-6e9a8b20527c:ibu-the-free-acid-is-required-event","event_type":"biochemical_relationship","label":"Cap the acid group and the drug can no longer settle into the slow, tenacious kind of binding.","description":"Conversion of the carboxylate moiety of flurbiprofen to an ester or amide abolishes slow tight-binding behaviour regardless of halogenation state, and contrary to prior predictions a halogen substituent is not sufficient to confer slow tight-binding behaviour.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"e5845bdb-6ff0-5a58-a1da-e7df95fb3f35","slug":"flurbiprofen","display_name":"Flurbiprofen","entity_type_key":"small_molecule"},"role":"modified_compound","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b429f269-1d01-59f4-881a-868de0849d0d","slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"},"role":"modified_compound","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"6284d26c-01e2-5e12-b192-ee391dd107e2","slug":"ptgs1","display_name":"Cyclooxygenase-1 (PTGS1)","entity_type_key":"protein"},"role":"target_enzyme","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"3252e719-ac25-56c8-b944-dd1f3a7cd1dc","slug":"carboxylate-anchor","display_name":"The free carboxylate group of a 2-arylpropionic acid inhibitor","entity_type_key":"protein_state"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"8a4b95c3-cebe-580a-b5a4-3b1aad8b8a1d","slug":"time-dependent-inhibition","display_name":"Time-dependent, slowly reversible inhibition of cyclooxygenase","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/ibuprofen-research/14741265.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"244b7634bca0e2a090e86f49257289d02d19637b2c540260e94662dcdaa4111a\", \"start_char\": 0, \"end_char\": 405, \"text_sha256\": \"244b7634bca0e2a090e86f49257289d02d19637b2c540260e94662dcdaa4111a\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Chemical modification of flurbiprofen and ibuprofen to alter cyclooxygenase-1 binding kinetics","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Halogenated and carboxylate-modified analogues tested for slow tight-binding behaviour","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A structure-activity result on the kinetic class of inhibition rather than on potency. It does not report the potencies themselves.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.","comparator":null,"unit":null,"notes":"","entity":{"slug":"ibuprofen","display_name":"Ibuprofen","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Enzyme","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Cap the acid group and the drug can no longer settle into the slow, tenacious kind of binding.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[ibu-p14741265] Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. (2004). https://pubmed.ncbi.nlm.nih.gov/14741265/ DOI: 10.1016/j.bmcl.2003.11.034","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Cyclooxygenase-1","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8a928920-767b-56e4-831b-d793a2393b08","evidence_kind":"source_excerpt","locator":"Lines 266-277","start_line":266,"end_line":277,"excerpt":"### ibu-the-free-acid-is-required\nConversion of the carboxylate moiety of flurbiprofen to an ester or amide abolishes slow tight-binding behaviour regardless of halogenation state, and contrary to prior predictions a halogen substituent is not sufficient to confer slow tight-binding behaviour.\nCondition category: normal\nnutrient_topic: Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers.\nplain_language: Cap the acid group and the drug can no longer settle into the slow, tenacious kind of binding.\norganism: Enzyme\ntissue_or_cell_type: Cyclooxygenase-1\nexperimental_model: Chemical modification of flurbiprofen and ibuprofen to alter cyclooxygenase-1 binding kinetics\nlimitations: A structure-activity result on the kinetic class of inhibition rather than on potency. It does not report the potencies themselves.\nexposure: Halogenated and carboxylate-modified analogues tested for slow tight-binding behaviour\nevidence_span: {\"source_cache\": \"artifacts/ibuprofen-research/14741265.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"244b7634bca0e2a090e86f49257289d02d19637b2c540260e94662dcdaa4111a\", \"start_char\": 0, \"end_char\": 405, \"text_sha256\": \"244b7634bca0e2a090e86f49257289d02d19637b2c540260e94662dcdaa4111a\"}\n[ibu-p14741265] Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. (2004). https://pubmed.ncbi.nlm.nih.gov/14741265/ DOI: 10.1016/j.bmcl.2003.11.034","model_system":"Chemical modification of flurbiprofen and ibuprofen to alter cyclooxygenase-1 binding kinetics","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [ibu-p14741265] Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. (2004). https://pubmed.ncbi.nlm.nih.gov/14741265/ DOI: 10.1016/j.bmcl.2003.11.034","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"31c4939d-f520-55c0-973b-224743caf245","stable_key":"import-3238e4f0-8d45-5c72-8624-6e9a8b20527c","title":"Ibuprofen: the enantiomer that works, the one that was called inactive, the one-way chemistry that turns one into the other, and the targets that are not cyclooxygenase (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"cc2b388178f97f5906b66ecbe441fc5c86d51fd645947c5260fb0b4bdb4bcd21","revision_id":"0b4e5c65-05d3-5430-a4cd-8d6a03647dcb","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}